抗菌Ceftolozane与人类炎症疾病点ADAM17之间的生物分子相互作用:一种药物重定向研究
Ahsan Anjoom Sunil1, Deepthi Jose2, Sai Kumar Karri1
1School of Biotechnology, National Institute of Technology Calicut, Calicut, India.
Journal of biomolecular structure & dynamics
|October 6, 2023
概括
抗菌药物ceftolozane可能会抑制ADAM17,这是炎症疾病的点. 然而,这种行为可能会增加出生缺陷的风险,因为它会干扰怀孕期间的EGF信号传输.
科学领域:
- 生物化学 生物化学
- 药理学 药理学是指药理学的学科.
- 药用化学 医学化学
背景情况:
- 抑制ADAM17是一种治疗策略,用于诸如类风湿性关节炎和炎症性肠病等炎症性疾病.
- 目前的ADAM17抑制剂面临毒性和临床进展的挑战.
- 对ADAM17的活性部位的联体结合,涉及Zn离子和疏水口袋,是抑制的关键.
研究的目的:
- 调查FDA批准的抗菌药物塞夫托洛,作为ADAM17的潜在抑制剂.
- 为了探索在ADAM17活性部位内Ceftolozane的结合相互作用.
主要方法:
- 密度函数理论 (DFT) 的计算.
- 分子对接模拟. 分子对接模拟.
- 使用ADAM17的催化链进行分子动力学模拟.
主要成果:
- 塞夫托拉的碳基团充当中度结合组.
- 它的结构在ADAM17活性部位内形成键和疏水相互作用.
- 塞夫托拉表现出与已知的ADAM17抑制剂相当的结合亲和力.
结论:
- 塞夫托洛在炎症条件下显示出调节ADAM17活性的潜力.
- ADAM17调解了EGF连接体的分离,这对胚胎发育至关重要.
- 在怀孕期间使用塞夫托洛赞可能会造成由于EGF信号受阻而导致出生缺陷的风险.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
154
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
154
Combined Effects of Drugs: Synergism
4.0K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Such synergistic combinations...
4.0K
Targets for Drug Action: Overview
6.3K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
6.3K
Gene Regulation in Microbial Communities: Quorum Sensing
24
Quorum sensing is a mechanism of bacterial communication that enables coordinated gene expression in response to changes in population density. This facilitates collective behaviors that enhance survival, resource acquisition, and ecological adaptation. This process relies on small signaling molecules called autoinducers that accumulate as bacterial populations grow. When a critical threshold concentration of autoinducers is reached, bacterial cells collectively modify gene expression,...
24
Combined Effects of Drugs: Antagonism
8.6K
The combined effects of drugs can result in various interactions, of which an important type is antagonism. Antagonism is a mechanism where one drug inhibits or counteracts the effects of another drug. Antagonism can occur through various means, including receptor binding, allosteric modulation, functional interaction, chemical reactions, and pharmacokinetic processes.
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...
8.6K
Inflammatory Bowel Disease IV: Pharmacological Management
137
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
137


